Home / Business and Economy / Moderna's RSV Vaccine Gets EU Green Light
Moderna's RSV Vaccine Gets EU Green Light
10 Jul
Summary
- Moderna's mRESVIA vaccine for RSV secured a contract for up to 24 million doses.
- The joint procurement contract with the European Commission will span up to four years.
- This deal expands Moderna's product offerings beyond its COVID-19 vaccine.
Moderna's stock saw a notable increase of 2.6% in afternoon trading on July 10, 2026, after the European Commission finalized a contract for up to 24 million doses of its Respiratory Syncytial Virus (RSV) vaccine, mRESVIA®.
This joint procurement, requested by six European nations, is set to run for a maximum of four years. The agreement is poised to open a substantial new market for Moderna's mRNA-based products, diversifying its portfolio beyond the widely recognized COVID-19 vaccine.
While the market responded positively, the movement suggests the news is significant but not a fundamental shift in perception. Moderna's shares have experienced considerable volatility, with numerous large percentage swings over the past year. The company has been actively preparing for expansion, appointing a new Chief Commercial Officer to oversee potential launches of up to three new products, including a flu/COVID combination vaccine and a norovirus vaccine, slated for 2027 and 2028.
